Marr, Alissa
https://orcid.org/0000-0002-2545-3570
Mayo Clinic
Fred and Pamela Buffett Cancer Center
Citations 2
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola
Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Achufusi, Amaka, Armand, Philippe , Bhatia, Shailender , Chokshi, Saurin , Davies, Marianne, Elshoury, Amro, Gesthalter, Yaron , Kaffenberger, Benjamin H. , Li, Tianhong , Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Oluwole, Olalekan O. , Patel, Sandip Pravin , Patil, Pradnya D. , Reddy, Sunil , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Lyons, Megan , Dwyer, Mary A., Hang, Lisa, Oluwole, Olalekan O , Kaffenberger, B , Ryder, Mabel , Berkenstock, Meghan , Budde, Lihua E. , Hegde, Aparna , Jain, Michael D. , Lechner, Melissa G , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G
Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 387-405
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.